RTP Mobile Logo
Oncology Nursing Update: Multiple Myeloma Edition, Issue 1, 2012
Released November 2012

Featuring interviews with Ms Jacy Spong and Dr Kenneth C Anderson. (Audio Content).

CE Disclosures and Faculty Information


    Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers and carries with it the worst death to new cases ratio (3:4) among all the blood cancer subtypes. Patients with smoldering (asymptomatic) myeloma may be cared for by observation only because the course of disease is often indolent for many years without therapy. However, patients with more advanced, active disease require immediate induction therapy in an effort to prepare eligible candidates for autologous stem cell transplant (ASCT). Optimal initial induction therapy for both ASCT candidates and those not eligible remains an area of clinical controversy, and multiple acceptable treatment options appear to merit consideration. Recent clinical research demonstrates an abundance of treatment options now available to patients with both newly diagnosed and relapsed or refractory MM. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with MM, the Oncology Nursing Update MM audio series employs one-on-one interviews with medical oncologists and nurses who are expert in caring for patients with MM. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with MM.

    • Discuss the benefits and risks associated with evidence-based systemic therapies used in the treatment of MM, including chemotherapy, proteasome inhibitors, corticosteroids and immunomodulatory agents, in the pre- and postautologous stem cell transplant (ASCT) settings and for patients who are not candidates for ASCT.
    • Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
    • Evaluate the preliminary safety profiles and response outcomes observed in studies of next-generation proteasome inhibitors and immunomodulatory agents for patients with relapsed or refractory and previously untreated MM.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


    This educational activity for 1.5 contact hours is provided by Research To Practice during the period of November 2012 through November 2013.


    This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.

    To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located at ResearchToPractice.com/ONUMM112/CNE. A statement of CNE credit will be issued only upon completion of the Post-test, with a score of 75% or better, and the Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jacy Spong, RN, BSN, OCN

    Mayo Clinic Scottsdale
    Scottsdale, Arizona

    No real or apparent conflicts of interest to disclose.

    Kenneth C Anderson, MD
    Kraft Family Professor of Medicine
    Harvard Medical School
    Chief, Division of Hematologic Neoplasia
    Director, Jerome Lipper Multiple Myeloma Center
    Director, LeBow Institute for Myeloma Therapeutics
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company, Nereus Pharmaceuticals, Onyx Pharmaceuticals Inc; Scientific Founder: Acetylon Pharmaceuticals Inc, OncoPep.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2012
    Expiration date: November 2013

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Oncology Nursing Update: Multiple Myeloma Edition, Issue 1, 2012
Released November 2012

Featuring interviews with Ms Jacy Spong and Dr Kenneth C Anderson. (Audio Content).

Read print: